Streetbeat News

Analyst Ratings

MRNS

Marinus Pharmaceuticals' stock has been downgraded from Outperform to Perform by Oppenheimer, with a new price target of $14. Other firms have also lowered their price targets for the stock.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 7:27 pm

THRN

Canaccord Genuity has maintained a Buy rating on Throne Healthtech's stock and raised its price target from $6 to $7. This has led to an increase in the trading of Throne Healthtech shares.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 7:15 pm

G

Needham analyst Mayank Tandon has reiterated the Buy rating on Genpact Limited (NYSE:G), but lowered the price target to $50 from $56. This follows Genpact's Q2 results, which showed a 2% Y/Y increase in total revenue to $1.106 billion, missing street view. The company's FY23 and FY24 revenue outlooks have been lowered due to ongoing economic uncertainty causing volume reductions and reduced ST project spend. Despite this, Tandon believes Genpact's demand for core BPO/analytics services remains strong and expects the company to deliver solid low-double-digit revenue growth.

Portfolio Pulse from Nabaparna Bhattacharya

August 11, 2023 | 7:13 pm

PFE

TBIO

KeyBanc Capital Markets analyst Paul Knight has downgraded Telesis Bio, Inc. (TBIO) to Sector Weight from Overweight, despite TBIO slightly exceeding consensus in 2Q23 results and progress in its technical collaboration with Pfizer, Inc. (PFE). The downgrade is due to limited top-line visibility and significant dilution from raising capital through an equity plus-warrant transaction. TBIO expects two more technical milestone achievements of ~$2.5 million each, one in 2H23 and the final in FY24. Pfizer has the option to trigger additional charges if the products meet certain clinical milestones.

Portfolio Pulse from Nabaparna Bhattacharya

August 11, 2023 | 7:09 pm

LULU

A significant amount of unusual options activity has been observed for Lululemon Athletica (NASDAQ:LULU), with a bullish stance taken by a majority of investors. The targeted price range for Lululemon Athletica over the last 3 months is from $330.0 to $500.0. The current price of LULU is $380.86, down by 0.96%. Keybanc maintains an Overweight rating on Lululemon Athletica with a price target of $425, while Telsey Advisory Group downgraded its action to Outperform with a price target of $430.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 7:01 pm

SLGL

In the last quarter, Sol-Gel Technologies (NASDAQ:SLGL) received 4 bullish analyst ratings. The average 12-month price target for the company, according to 4 analysts, is $13.5, with a high of $19.00 and a low of $7.00. This average price target has increased by 42.11% over the past month.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 7:00 pm

MRO

Over the past 3 months, 12 analysts have published their opinion on Marathon Oil (NYSE:MRO) stock. The analysts have an average price target of $30.83 versus the current price of Marathon Oil at $26.945, implying upside. This current average represents a 8.6% decrease from the previous average price target of $33.73.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 7:00 pm

EYE

National Vision Holdings (NASDAQ:EYE) has received one bullish and four indifferent analyst ratings in the last quarter. The average 12-month price target for the company is $22.0, representing an 11.29% decrease from the previous average price target of $24.80.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 7:00 pm

ALXO

Over the past 3 months, 4 analysts have published their opinion on ALX Oncology Holdings (NASDAQ:ALXO) stock. The analysts have an average price target of $16.0 versus the current price of ALX Oncology Holdings at $5.05, implying upside. This current average has decreased by 52.0% from the previous average price target of $33.33.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 7:00 pm

KGS

In the last quarter, Kodiak Gas Services (NYSE:KGS) received 8 bullish and somewhat bullish ratings from analysts, with an average 12-month price target of $22.88, an increase of 8.95% from the previous average price target of $21.00.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 7:00 pm